Spread-out Bragg peak FLASH: quantifying normal tissue toxicity in a murine model

July 2024 in “ Frontiers in Oncology ”

Line Kristensen, P.R. Poulsen, Eleni Kanouta, Sky Rohrer, C. Ankjærgaard, C.E. Andersen, Jacob Johansen, Yuri Simeonov, Uli Weber, Cai Grau, Brita Singers Sørensen

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on frontiersin.org →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community Trial for TDM-105795 update from research office

in Research/Science 17 upvotes 2 years ago

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 30 upvotes 2 months ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

community PP405 2a study was a safety study. Some rational explaining.

in Research/Science 22 upvotes 9 months ago

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found

in Research/Science 47 upvotes 3 years ago

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

community PP405 (Non) Update - Feb 2025

in Research/Science 34 upvotes 1 year ago

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

community Amplifica AMP-303 study results are expected late this summer

in Research/Science 15 upvotes 1 year ago

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.